Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JUN | P05412 | 12/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 12/20 | 0.63 |
| ▸ | NFKB2 | Q00653 | 12/20 | 0.63 |
| ▸ | RELA | Q04206 | 12/20 | 0.63 |
| ▸ | XPO1 | O14980 | 8/20 | 0.48 |
| ▸ | FOS | P01100 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2576791 | 0.78 | JUN (1.00) | JUNNFKB1NFKB2RELAFOS | |
| SCHEMBL5928385 | 0.68 | JUN (0.57) | JUNNFKB1NFKB2RELAXPO1 | |
| SCHEMBL541611 | 0.58 | JUN (0.64) | JUNNFKB1NFKB2RELAXPO1 | |
| SCHEMBL23094631 | 0.57 | NFKB1 (0.42) | JUNNFKB1NFKB2RELA | |
| SCHEMBL16647331 | 0.56 | LMNA (0.42) | — | |
| SCHEMBL21240967 | 0.55 | LMNA (0.38) | — | |
| SCHEMBL15994288 | 0.55 | LMNA (0.33) | XPO1 | |
| SCHEMBL15871697 | 0.55 | KDM4E (0.55) | — | |
| SCHEMBL29639807 | 0.54 | NFKB1 (0.42) | JUNNFKB1NFKB2RELAXPO1 | |
| SCHEMBL15730150 | 0.54 | GAA (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415765-A1 | PYRIMIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2012-02-08 | — | — | EP | claimed |
| US-20110053912-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-03-03 | — | — | US | claimed |
| US-20130310373-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-11-21 | — | — | US | disclosed |
| US-8524727-B2 | Pyrimidine compound | ASTELLAS PHARMA INC. (JP) | 2013-09-03 | — | — | US | disclosed |
| EP-2415765-A1 | PYRIMIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20110053912-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053912-A1 | PYRIMIDINE COMPOUND | CNR2, CNR1, P2RY2 | JUN 242/4885NFKB1 2708/4885NFKB2 2655/4885 |
| US-20130310373-A1 | PYRIMIDINE COMPOUND | CNR2, CNR1, P2RY2 | JUN 324/4885NFKB1 2619/4885NFKB2 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.